ATLANTA, GA – – (May 16, 2018) – – Holzer & Holzer, LLC is investigating whether Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) complied with the federal securities laws. On May 16, 2018, Evolus announced that the FDA sent a Complete Response Letter related to the Company’s Biologics License Application for DWP-450, a developmental treatment of frown lines. The FDA’s Complete Response Letter noted deficiencies in Evolus’ Chemistry, Manufacturing and Controls processes. The price of Evolus stock fell following the announcement. If you purchased Evolus common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Alexandria P. Rankin, Esq. at email@example.com, or call the firm by toll-free telephone at (888) 508-6832.